Supplementary MaterialsSupplementary Information, Appendix A 41598_2019_39335_MOESM1_ESM. products1. PPIs have demonstrated superior

Supplementary MaterialsSupplementary Information, Appendix A 41598_2019_39335_MOESM1_ESM. products1. PPIs have demonstrated superior efficacy to histamine-2 receptor antagonists (H2RAs) in treatment of acid-related disorders and have replaced the H2RAs2,3. The current indications include treatment of gastroesophageal reflux disease, non-steroidal anti-inflammatory drug (NSAID) and induced ulcers, duodenal ulcers, erosive esophagitis, and other pathological hypersecretory conditions, including Zollinger-Ellison syndrome4,5… Continue reading Supplementary MaterialsSupplementary Information, Appendix A 41598_2019_39335_MOESM1_ESM. products1. PPIs have demonstrated superior